There is increasing interest in antipsychotics intended to manage positive symptoms via D2 receptor blockade and improve negative symptoms and cognitive deficits via 5-HT1A receptor activation (Newman-Tancredi and Kleven, 2011). The gene discussed is HTR1A; the disease is Cognitive impairment.